Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
April 24, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
March 31, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Financing by new and existing institutional...
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 06, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and...
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 27, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute...
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 02, 2023 08:30 ET
|
Unicycive Therapeutics, Inc.
Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE...
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 23, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 05, 2023 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 29, 2022 11:31 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 28, 2022 08:30 ET
|
Unicycive Therapeutics, Inc.
Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance...
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 22, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease,...